摘要
目的:评价3种用药方案治疗椎基底动脉供血不足的疗效及成本-效果。方法:将90例椎基底动脉供血不足的患者随机分成3组,除均给予盐酸氟桂利嗪外,A、B、C组再分别给予盐酸丁咯地尔、舒血宁、复方丹参治疗14d。结果:A、B、C组成本分别为1705.06、2876.30、1117.34元,总有效率分别为93.75%、92.86%、70.00%,成本-效果比分别为1818.73、3097.46、1596.20,A、B组对于C组的增量成本-效果比分别为2474.61、7694.49。结论:A组方案较佳。
OBJECTIVE： To evaluate the therapeutic effects and cost - effectiveness of 3 therapeutic regimens in the treatment of vertebrobasilar ischemia. METHODS： 90 cases with vertebrobasilar ischemia were randomly divided into 3 groups： Group A were assigned to receive buflomedil ＋ Flunarizine, Group B to receive Shuxuening ＋ Flunarizine and Group C to receive compound Compound Danshen ＋ Flunarizine. The curative effects and the cost - effectiveness of the 3 Groups after 14- day treatment were analyzed comparatively. RESULTS： The total costs for Group A, B and C were 1 705.06 yuan, 2 876.30 yuan and 1 117.34 yuan, respectively; the effective rates were 93.75%, 92.86% and 70.00%, respectively; the cost- effectiveness ratios were 1 818.73, 3 097.46 and 1 596.20, respectively. As compared with Group C, the incremental costs- effectiveness ratios for Group A and Group B were 2 474.61 and 7 694.49, respectively. CONCLUSION： Group A is more preferable among the 3 therapeutic regimens in terms of cost- effectiveness.
出处
《中国药房》
CAS
CSCD
北大核心
2008年第17期1291-1293,共3页
China Pharmacy
关键词
椎基底动脉供血不足
用药方案
成本效果分析
Vertebrobasilar ischemia
Therapeutic regimen
Cost - effectiveness analysis
